Febuxostat is preferred over allopurinol in a patient with gout and CKD stage 3b. The pharmacological reasoning is:

• A Febuxostat is a competitive xanthine oxidase inhibitor while allopurinol is non-competitive, making febuxostat more potent
• B Febuxostat selectively inhibits the oxidized form of xanthine oxidase while allopurinol also inhibits purine salvage enzymes, causing immunosuppression in CKD
• C Febuxostat reduces tubular urate reabsorption in addition to xanthine oxidase inhibition, providing dual urate-lowering benefit in CKD
• D Febuxostat is primarily hepatically metabolized and minimally renally excreted, requiring no dose adjustment in mild-moderate CKD, while allopurinol's active metabolite oxypurinol accumulates in renal impairment causing serious adverse effects (allopurinol hypersensitivity syndrome, myelosuppression) ✓

Explanation

Febuxostat is a non-purine, selective xanthine oxidase inhibitor (inhibits both reduced and oxidized forms, making it non-competitive in character). It is extensively metabolized by conjugation (glucuronidation) and oxidative pathways in the liver; only 6% is excreted renally unchanged, requiring no dose adjustment in mild-to-moderate CKD. Allopurinol's active metabolite oxypurinol is almost entirely renally excreted; in CKD, oxypurinol accumulates, dramatically increasing the risk of allopurinol hypersensitivity syndrome (AHS) — a severe reaction including TEN, SJS, and multi-organ failure — particularly in HLA-B*58:01 carriers (East/South Asian populations). Febuxostat also lacks the xanthine oxidase substrate analog structure that causes allopurinol's purine metabolic pathway interference.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.